Inozyme Pharma Q1 EPS $(0.38) Misses $(0.36) Estimate
Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 5 percent increase over losses of $(0.40) per share from the same period last year.